Contingency management (CM) is associated with decreases in off-target drug and alcohol use during primary target treatment. The primary hypothesis for this trial was that targeting alcohol use or tobacco smoking would yield increased abstinence in the opposite, nontargeted drug. We used a 2 [CM vs. noncontingent control (NC) for alcohol] × 2 (CM vs. NC for smoking tobacco) factorial design, with alcohol intake (through urinary ethyl glucuronide) and tobacco smoking (through urinary cotinine) as the primary outcomes. Thirty-four heavy-drinking smokers were randomized into one of four groups, wherein they received CM, or equivalent NC reinforcement, for alcohol abstinence, smoking abstinence, both drugs, or neither drug. The CM for alcohol and tobacco group had only two participants and therefore was not included in analysis. Compared with the NC for alcohol and tobacco smoking group, both the CM for the tobacco smoking group [odds ratio (OR) = 12.03; 95% confidence interval (CI): 1.50-96.31] and the CM for the alcohol group (OR = 37.55; 95% CI: 4.86-290.17) submitted significantly more tobacco-abstinent urinalyses. Similarly, compared with the NC for the alcohol and tobacco group, both the CM for smoking (OR = 2.57; 95% CI: 1.00-6.60) and the CM for alcohol groups (OR = 3.96; 95% CI: 1.47-10.62) submitted significantly more alcohol-abstinent urinalyses. These data indicate cross-over effects of CM on indirect treatment targets. Although this is a pilot investigation, it could help to inform the design of novel treatments for alcohol and tobacco co-addiction. Behavioural Pharmacology 29:462-468
Introduction
Together, tobacco, and alcohol kill more than a half a million individuals in the USA every year (Li et al., 2007; Kalman et al., 2010; Sacks et al., 2013; Apollonio et al., 2016; Xu et al., 2017) , and addiction to these substances represents the leading causes of preventable death (Johnson, 2004; Li et al., 2007) . Some tobacco smoking prevalence estimates are reported to be as high as 80% among clinical populations with an alcohol use disorder (Kalman et al., 2005; Hendrickson et al., 2013) . There is also a synergistic risk when both these substances are used concurrently, which multiplies many health risks already at work when each substance is used independently (Hurt et al., 1996; Castellsagué et al., 1999; Pelucchi et al., 2006) . Both drugs exert their reinforcing effects through mesolimbic pathways and complex interactions with dopamine and other neurotransmitters (Soderpalm et al., 2000; Hendrickson et al., 2013; Tolu et al., 2017) , including nicotinic acetylcholine receptors (Gianoulakis, 2004; Chatterjee and Bartlett, 2010; Nocente et al., 2013) . Unfortunately, the current understanding of these biological factors has not yet improved the effective treatment of tobacco smoking and alcohol use disorders. Understanding the comparative reinforcement provided by both substances is necessary to test hypotheses on the integration of alcohol use disorder treatment with smoking-cessation treatment and other types of co-addiction, Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.behaviouralpharm.com.
for example, sequencing of treatments, timing, and lead-in periods.
Contingency management (CM) is one of the most effective behavioral interventions for initiating abstinence from illicit and nonillicit drugs (Stitzer et al., 1979; Higgins et al., 1986 Higgins et al., , 1994 Budney et al., 2000; Robles et al., 2002; Roll, 2007; Dutra et al., 2008) . Using operant conditioning, an alternative, non-drug-reinforcing reward (prizes or monetary incentives) is given in exchange for negative urine samples, thus reinforcing abstinence (Bigelow and Silverman, 1999) . Our group has found that CM has decreases in off-target drug and alcohol use (McDonell et al., 2013) and off-target increases in treatment attendance (McPherson et al., 2016; McDonell et al., 2017) .
At the same time, CM has not been applied widely as a behavioral treatment for alcohol use disorders, given the methodological difficulty of detecting abstinence using standard breath alcohol test procedures (McDonell et al., 2011a; Lowe et al., 2015) . This randomized-controlled analog trial (RCaT) addresses this critical methodological barrier by using a superior alcohol measure, ethyl glucuronide (EtG) urine tests, which can detect alcohol use for up to 5 days after drinking has occurred (Wurst and Metzger, 2002; Helander et al., 2009; Litten et al., 2010; McDonell et al., 2011b; Leickly et al., 2015) . We also used cotinine as our primary smoking measure.
Given previous evidence of the synergistic biochemical relationship between alcohol and tobacco use, we hypothesized that targeting one substance would increase abstinence in the other nontargeted substance. We conducted this RCaT in a population of heavy-drinking tobacco smokers, targeting both alcohol and tobacco smoking with CM concurrently, to directly compare the impact of equivalent reinforcement levels on abstinence from these neurobiologically and behaviorally linked substances. Analog trials are a commonly used method of examining an experimental behavioral treatment with a small sample of non-treatment-seeking patients (Packer et al., 2012; McPherson et al., 2014) . These trials can be useful in the design of future, potentially promising treatment that may be ready for a larger clinical trial. The primary aim of this investigation was to understand how equivalent reinforcement levels would impact both ontarget and off-target substances (i.e. alcohol and tobacco use) in a population of heavy-drinking smokers who were nontreatment seeking.
Methods

Participants
Our target demographic for recruitment included participants with a Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) diagnosis of alcohol dependence, abuse or reported heavy drinking (six or more drinks, ≥ 4 days in a week for men and five or more drinks, ≥ 4 days in a week for women) with a co-occurring DSM-IV-TR diagnosis of nicotine dependence, abuse, or reported heavy use (>10 cigarettes/day and Smokerlyzer carbon monoxide value of > 9 ppm) who were not seeking treatment. Recruitment of those who are not seeking treatment is a common method for examining experimental behavioral therapeutics, such as the one under investigation in this study, to (i) maintain the highest ethical standards of not providing an untested treatment to individuals who are seeking evidence-based care, (ii) provide the most rigorous examination of efficacy, and (iii) provide homogeneity among participants in their motivation to change their use of the substances under investigation. Participants were recruited through advertisements, Craigslist, and classified ads around a city in the northwestern USA. Interested individuals contacted study staff, who explained the study and screened for recent alcohol and tobacco use. Eligible participants (see the section Participant Eligibility) were scheduled for an in-person visit and they provide written informed consent. This study was approved for human participants by the Washington State University Institutional Review Board. Informed consent was obtained from all participants before participation in study activities.
Design
We chose a 2 × 2 factorial design for this RCaT, with alcohol and tobacco smoking as our co-primary, biochemically verified outcomes. Participants were screened by phone for initial criteria, and if found to be eligible, were invited to come to the laboratory for a baseline visit. After completing the baseline visit, eligible participants were randomized into one of four groups (see Supplementary Fig. 1 , Supplemental digital content 1, http://links.lww.com/BPHARM/A14, for reinforcement schedule, potential earnings, and the range of reinforcement provided): (i) NC (control) for alcohol and tobacco, (ii) CM for alcohol and NC (control) for tobacco, (iii) NC (control) for alcohol and CM for tobacco, and (iv) CM for alcohol and tobacco. No participants in this group attended more than one visit and this group was therefore not included in the analysis. Importantly, the planned and actual reinforcement provided across all four of the conditions was equivalent, as shown in Supplementary Fig. 1 (Supplemental digital content 1, http://links.lww.com/ BPHARM/A14). This is a notable observation in itself because several participants, on finding out that they were going to be incentivized to be abstinent from both smoking and alcohol consumption, decided that they did not want to participate. Although these are all non-treatment-seeking participants, this observation speaks to a likely need for high-intensity treatment when targeting both alcohol and smoking.
Experimental behavioral intervention
All groups were scheduled for three visits per week for a 4-week period, where they provided urine and breath samples, and completed questionnaires to assess several aspects related to recent alcohol use, tobacco smoking, withdrawal, and cravings. Participants in the CM groups received escalating monetary reinforcement, on the basis of the duration of abstinence, biochemically verified by urine samples from the targeted substance or substances. Positive samples earned the participant no rewards, and upon the next negative sample, rewards were reverted to the start amount. Participants in the NC for alcohol and tobacco group received monetary reinforcement irrespective of the status of their urine sample. Participants received monetary reinforcement one visit after the visit, wherein they provided a urine sample. This delay was because of the time required for samples to be sent to a local lab and processed for EtG. This methodology has been used previously and has been shown to be effective (McDonell et al., 2012) .
Measures
Alcohol and tobacco abstinence was verified biochemically through provisioned urine samples from participants. Recent 24-h alcohol use and tobacco smoking was assessed by a Breathalyzer (Intoximeters; St. Louis, Missouri, USA) and a Smokerlyzer (Bedfont Scientific; Harrietsham, Maidstone, Kent, ME171JA, England). Use over the past 72 h was assessed through self-report at each visit.
Baseline measures
At baseline, participants completed the Addiction Severity Index (McLellan et al., 1992 (McLellan et al., , 2006 Appleby et al., 1997) to assess self-reported alcohol and drug use and the impact of alcohol and drug use on psychiatric, legal, medical, and family functioning. Tobacco and alcohol-use disorders were assessed using the Mini Interventional Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) , the Fagerström Test for Nicotine Dependence (Korte et al., 2013) , and the Alcohol Use Disorders Identification Test (Piccinelli et al., 1997) . General physical and mental health was captured by the Brief Symptom Inventory (Preston and Harrison, 2003) , the HIV Risk-Taking Behavior Scale (Darke et al., 1991) , and the RAND 36-Item Health Survey 1.0 Questionnaire (Vander Zee et al., 1996) .
Alcohol use and tobacco smoking biomarkers
At each study visit, urine samples were collected and analyzed for EtG and cotinine using Diagnostic Reagents Incorporated EtG and Diagnostic Reagents Incorporated Cotinine semi-quantitative enzyme immunoassay tests performed by a local independent company, Absolute Drug Testing, Spokane, Washington, USA. Alcohol use was determined by detection of EtG, using a cutoff level of 200 ng/ml, as this level has been shown to accurately detect 80% of clinically significant drinking for up to 5 days (McDonell et al., 2012 Leickly et al., 2015; Lowe et al., 2015) . Tobacco smoking was determined by detection of cotinine using a threshold of 100 ng/ml, an established cutoff for detecting cigarette smoking in the past 5-7 days (Bernert et al., 1997; Benowitz, 1999; Cooke et al., 2008) .
Recent alcohol and tobacco use were measured by breath samples. A Micro Smokerlyzer (Bedfont Scientific Ltd., Rochester, UK) assessed recent tobacco smoking by measuring carbon monoxide levels and Alco-Sensor III Intoximeters Inc. (Saint Louis, Missouri, USA) measured breath alcohol concentration (Gibb et al., 1984; Al-Sheyab et al., 2015) .
Self-reported alcohol and drug measures
During the baseline assessment, demographic characteristics were collected by self-report using the Addiction Severity Index noted above. At baseline, self-reported alcohol and tobacco use was assessed using the Alcohol and Tobacco Timeline Followback method (Sobell and Sobell, 2000; Pedersen and LaBrie, 2006) , in which participants report the frequency and quantity of their daily drinking and smoking for the 30 days before the baseline visit. During the study visits, the Timeline Followback method was used to assess alcohol and tobacco daily use. At each visit, alcohol and tobacco 'craving' were assessed by Visual Analog Scales and the Questionnaire of Smoking Urges, respectively, with a 10 cm Visual Analog Scale anchored at 0 (no craving) and 100 (most intense craving possible) (Toll et al., 2006) .
Participant eligibility
Eligibility criteria were as follows: (i) age 18 years and older, (ii) DSM-IV-TR diagnosis of current alcohol abuse or dependence per the MINI (a semistructured clinical interview) or heavy alcohol use as defined by six or more drinks, 4 or more days in a week for men and five or more drinks, 4 or more days in a week for women , (iii) DSM-IV-TR diagnosis of current tobacco abuse or dependence per the MINI or heavy tobacco use as defined by more than 10 cigarettes/day and Smokerlyzer carbon monoxide value of greater than 9 ppm , (iv) not seeking treatment for either substance, (v) ability to read and speak English, and (vi) ability to provide written informed consent.
Exclusion criteria were as follows: (i) significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure in the last 12 months, (ii) expressed concern about dangerous withdrawal, (iii) attempted suicide in the past year, (iv) any other medical or psychiatric condition that the Principal Investigator or Medical Director determined would compromise safe study participation, (v) breath alcohol content above 0.00 at the time of informed consent, and (vi) positive baseline urine analysis for benzodiazepines (because of benzodiazepines being prescribed for alcohol withdrawal).
Statistical analysis
We computed means and SDs for continuous variables, and percentages and frequencies for categorical variables, as shown in Table 1 for all baseline characteristics. We carried out analyses of variance to determine whether participants differed across continuous variables at baseline, and we calculated χ 2 -statistics on categorical variables at baseline to determine whether participants differed across categorical variables. For the primary outcome analyses that used the above-noted cutoffs to determine whether an individual's sample was positive or negative, we utilized generalized estimating equations to examine change in alcohol use and smoking across the 4-week experimental intervention period. Because we removed one of our four experimental groups, because of the lack of participants and the other groups covering the substances, we converted our original 2 × 2 factorial into a three-group categorical variable that was used as the primary independent variable. The control group (NC for alcohol tobacco) was the referent group for all analyses.
We also carried out secondary analyses on quantitative change in EtG and cotinine using generalized estimating equations, but instead of the logit link for binary outcomes, as needed for the primary outcomes, we used the identity link to examine changes in the continuous versions of EtG and cotinine. Missing data were handled in a manner consistent with standard generalized estimating equation procedures; if a participant contributed two or more data points in the longitudinal analysis, they were included in the model, that is, individuals with two or more outcome values were included in the analysis, which was everyone who made it to the first visit. This meant that all of our intention-to-treat samples were included for all of our analyses. We used an α threshold of 0.05 as the cutoff for determining statistical significance.
All analyses were carried out in Stata 14.2 (StataCorp., College Station, Texas, USA).
Results
Baseline characteristics
Five hundred potential participants form the surrounding community were screened, resulting in 34 eligible and randomized participants ( Supplementary Fig. 2 , Supplemental digital content 2, http://links.lww.com/ BPHARM/A15). Demographic data of randomized participants showed that 68% of our sample included men, 79% were White, and 11% were multiracial. The average age was 36 years (range: 20-59 years). At baseline, 97% of participants tested positive for cotinine and 65% tested positive for EtG. Participants had an average carbon monoxide value of 17.7 ppm (range: 3-47 ppm). Among the randomized participants, 9% tested positive for methamphetamine and 50% tested positive for cannabis. Finally, 3% tested positive for methadone and 6% tested positive for opioids. Baseline characteristics by group are presented in Table 1 . All participants in the CM for both the alcohol and tobacco group (n = 8) dropped out by study visit 3 and thus were not included in the analysis. The three remaining experimental groups did not differ significantly across any of the baseline characteristics (P > 0.05).
Primary binary biochemical outcomes
The CM for tobacco NC for alcohol group submitted significantly more tobacco-abstinent urinalyses (UAs) compared with the NC for the alcohol and tobacco group [odds ratio (OR) = 12.03, P < 0.05; 95% confidence interval (CI): 1.50-96.31; Fig. 1] . Similarly, the CM for alcohol NC for tobacco group (OR = 37.55, P < 0.05; 95% CI: 4.86-290.17) also submitted significantly more tobacco-abstinent UAs compared with NC for the alcohol and tobacco group. The CM for tobacco, NC for alcohol group, compared with the control (i.e. NC for alcohol and tobacco) group, also submitted significantly more alcohol-abstinent UAs (OR = 2.68, P < 0.05; 95% CI: 1.33-5.38). The CM for alcohol, NC for tobacco group (OR = 4.07, P < 0.05; 95% CI: 1.95-8.46) submitted significantly more alcohol-abstinent UAs compared with NC for both drugs.
Secondary quantitative biochemical outcomes
The CM for tobacco, NC for alcohol group did not submit significantly lower EtG urine levels compared with the NC for alcohol and tobacco group (B = − 151.95 ng/ml, P > 0.05; 95% CI: − 414.16 to 110.26 ng/ml). However, the CM for alcohol, NC for tobacco group did submit significantly lower EtG urine levels compared with the NC for alcohol and tobacco group (B = − 386.57 ng/ml, P < 0.05; 95% CI: − 668.01 to − 105.12 ng/ml). The CM for tobacco, NC for alcohol group, compared with the control group, also submitted significantly lower cotinine urine levels (B = − 214.58 ng/ml, P < 0.05; 95% CI: − 373.39 to − 55.76 ng/ml). Finally, the CM for alcohol, NC for tobacco group (B = − 580.06 ng/ml, P < 0.05; 95% CI: − 750.53 to − 409.59 ng/ml) submitted significantly lower cotinine urine levels compared with the NC for alcohol and tobacco group. See Supplementary Fig. 3 (Supplemental digital content 3, http://links.lww.com/BPHARM/A16) for a depiction of both EtG-negative and cotinine-negative sample submissions over time during the experimental intervention.
Discussion
We conducted an RCaT to examine the potential onand-off-target effects of CM on co-occurring tobacco smoking and alcohol use. Although both the CM for tobacco NC for alcohol group and the CM for alcohol NC for tobacco group submitted significantly more abstinent UAs for both substances when analyzing the biomarkers in a binary manner, the CM for tobacco group submitted significantly more negative urine samples for the offtarget substance of alcohol, whereas the CM for alcohol group showed smaller off-target effects for tobacco. Thus, on the basis of our findings, CM for tobacco was more effective for decreasing both alcohol and tobacco, than CM for alcohol. Future behavioral studies should consider focusing on the behavioral link between tobacco and alcohol when optimizing interventions for this co-occurring addiction. Specifically, future intervention designs should consider whether to 'weight' the intervention in question more heavily toward the treatment of tobacco or more toward alcohol. Previous research found that increases in tobacco prices increased alcohol use, whereas increases in alcohol use resulted in decreases in both substances (Decker and Schwartz, 2000) .
Although the study has a small sample size and has a large range of confidence intervals, we believe that it provides an important signal, warranting further study of co-occurring substance abuse with CM. This novel design and analog methodology will allow for the examination of the comparative or relative reinforcement between two related, but distinct, drugs of abuse that are linked neurobiological and behaviorally (Soderpalm et al., 2000; Gianoulakis, 2004; Chatterjee and Bartlett, 2010; Nocente et al., 2013) . Such co-occurring addictions are ubiquitous in the realm of substance-use disorder treatment and are in need of significantly increased understanding with respect to their relative reinforcement to optimize co-morbid treatment options. Our analog methodology is proposed as a possible first step for understanding the basics of comparative reinforcement between two drugs when used in tandem and how behavior change can or cannot be achieved when there is an attempt to exploit their inherent linkage. A better understanding of how to quantify and exploit this linkage may help inform a model that will be applicable to the treatment of several other co-occurring addictions. Also, although the reinforcement that we provided was monetarily equivalent across groups and across the substances, establishing what equivalent reinforcement units are between different substances can be challenging and further complicates understanding and treating co-addiction.
Another complicating factor to consider in the design of novel treatments for this population is psychiatric comorbidity. As noted previously, we have found off-target effects of CM on smoking in both psychostimulant use disorder and alcohol use disorder populations with psychiatric co-morbidities (McDonell et al., 2012 (McDonell et al., , 2014 Average number of negative urine samples submitted during follow-up across groups (missing visits coded as positive). CM, contingency management; NC, noncontingent control; UA, urinalyses. Bellack et al., 2006; McDonell et al., 2013; Kelly et al., 2014) . This is further justification for examining variants of CM as a method of increasing abstinence among patients with a co-addiction.
Importantly, a few months before the implementation of this study, Washington legalized recreational cannabis use. Therefore, the exclusion of those who tested positive for tetrahydrocannabinol at baseline was removed from the protocol before implementation. Given the ubiquity of cannabis use throughout the state and the increased prevalence rates after legalization, this is the standard for several on-going studies. This was evidenced in the current investigation as 50% of the participants thus far have tested positive for tetrahydrocannabinol. This change makes the study more applicable to a community setting as more states legalize recreational cannabis use.
During the initiation of this investigation, and in an effort to better capture the population of non-treatmentseeking individuals, the inclusion criteria of a DSM-IV-TR diagnosis of alcohol dependence or abuse and nicotine dependence or abuse were widened to heavy users of both substances. Clinically, this change indicates our willingness to recruit participants who smoke or drink high amounts, but are not classified as dependent. This is an important group to include because our findings will likely generalize to this population for future treatment design considerations. Indeed, as increasingly more treatment agencies rely less on DSM diagnoses and more on self-reported use thresholds, RCaT studies or similar studies will more readily translate to treatment settings after collecting experimental treatment evidence. Moreover, this is a high-risk group of smokers at severe risk for several tobacco-associated health problems, which are magnified when accounting for their heavy drinking. Special attention needs to be paid to those with co-addiction as no participant attended more than one visit in our CM for both the alcohol and smoking group, indicating a need for higher intensity treatment among individuals wanting to receive treatment for two addictions.
Compared with other, previously reported RCaT-type studies conducted in our laboratory that usually enroll between 25 and 50% of screened participants, our 12% enrollment rate in this experiment is notably low, even among non-treatment-seeking populations (McDonell et al., 2012; Packer et al., 2012; McPherson et al., 2014) . This may be indicative of a need to increase the amount of reinforcement delivered during future, RCaT experiments. As noted above, the development of experimental, co-occurring addiction treatments should start with either this or a similar design to first understand the basic comparative reinforcement properties when two or more substances are used in tandem (McDonell et al., 2012; Packer et al., 2012) .
